Skip to main content

Table 1 The main detailed characteristics of the included studies

From: A meta-analysis of the efficacy and safety of accelerated partial breast irradiation versus whole-breast irradiation for early-stage breast cancer

Author/year

Follow-up (years)

Study Period

Sample Size (n, APBI/WBI)

Jadad score

Age (years)

Stage

Receptor status

Premen-opausal

Histology

Treatment arms

Jayant 2020 [23]

9

2004–2012

581/572

5

63

0 ~ II

ER + :98%

HER2 + :5.5%

NR

Grade 3: 5.6%

IDC:100%

APBI: 50 kV energy X-rays IORT 20 Gy

WBI:EBRT40–56 Gy/15–25F ± boost10–16 Gy/5–8F

Vicini 2019 [24]

10.2

2005–2013

2036/2089

5

54

0 ~ II

ER + :81%

HER2 + :NR

39%

Grade 3: 26.8%

DCIS: 24.5%

APBI: HDR brachytherapy 34 Gy or 3DCRT 38.5 Gy/10F, BID

WBI: EBRT 50 Gy/25F ± Boost 10 Gy/5 F at least

Whelan 2019 [18]

8.6

2006–2011

1070/1065

5

61

0 ~ II

ER + :90%

HER2 + :4.7%

NR

Grade 3: 12.9%

DCIS: 18%

APBI: 3DCRT or IMRT 38.5 Gy/10F,BID

WBI: External beam 42.5 Gy/16F or 50 Gy/25F ± Boost 10 Gy/5F

Coles 2017 [25, 26]

6.1

2007–2010

669/674

5

62

I ~ II

ER + : 95.1%

HER2 + : 4%

NR

Grade 3: 9.5%

IDC: 85.4%

APBI: IMRT 40 Gy/15F

WBI: IMRT 40 Gy/15F

Strnad 2016 [19]

6.6

2004–2009

633/551

7

62

0 ~ IIA

ER + :91.4%

HER2 + :NR

16.9%

Grade 3: 8.4%

IDC: 74.1%

APBI: HDR brachytherapy 32 Gy/8F or 30.1 Gy/7F BID

PDR brachytherapy 50 Gy/0.6–0.8 Gy/per h pulses,24 h/day

WBI: (4–10MV) photon beams 50.0–50.4 Gy /25–28F ± Boost 10 Gy/5F

Livi 2015 [27, 28]

5

2005–2013

260/260

5

60–69

I ~ II

ER + : 95.4%

HER2 + :3.6%

NR

Grade 3:11.4%

IDC: 57.5%

DCIS: 10.6%

APBI: IMRT 30 Gy/5F

WBI: IMRT 50 Gy/25F + Boost 10 Gy/5F

Vaidya 2014 [29, 30]

2.4

2000–2002

1679/1696

5

61–70

I ~ IIIA

ER + :93%

HER2 + :11.6%

NR

Grade 3: 15.2%

IDC: 100%

APBI: 50 kV energy X-rays IORT 20 Gy

WBI: EBRT40–56 Gy/15–25F ± boost10–16 Gy/5–8F

Polgár 2013 [31]

10.2

1998–2004

128/130

4

58.5

I ~ II

ER + :88.7%

HER2 + :NR

21.3%

Grade 3: 0%

IDC: 81.8

APBI: HDR brachytherapy 36.4 Gy/7F, BID; Protocol allowed 50 Gy limited field electron beam if patients unsuitable for brachytherapy

WBI: Telecobalt or 6–9MV photon beams using wedged tangential fields 42–50 Gy/2 Gy per day

Veronesi2013 [32]

5.8

2000–2007

651/654

5

60–69

I ~ II

ER + : 90.8%

HER2 + :3.4%

NR

Grade 3: 21.7%

IDC: 80.2%

APBI: Electron IORT 21 Gy

WBI: EBRT 50 Gy/25F + Boost 10 Gy/5F

Rodriguez 2013[33]

5

NR

51/51

4

68.6

I ~ II

ER + : 98%

HER2 + : 1%

0%

Grade 3: 0%

ILC excluded

APBI: 3DCRT 37.5 Gy/10F,BID

WBI: 3DCRT 48 Gy/24F ± Boost 10 Gy/5F

  1. IMRT intensity-modulated radiation therapy, IORT intraoperative irradiation, 3DCRT three-dimensional conformal radiation therapy, EBRT whole-breast external beam radiotherapy, HDR high dose rate, WBI whole-breast irradiation, APBI accelerated breast irradiation, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IDC invasive duct carcinoma, DCIS ductal carcinoma in situ, ILC invasive lobular carcinoma, BID Boost tumor bed, two fractions per day, NR not reported